United Kingdom· GB-APID-40063211000001105
Imdevimab 120mg/ml solution for infusion 11.1ml vials
A medicinal product containing imdevimab, registered in United Kingdom by Roche Products Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Imdevimab
- Manufacturer
- Roche Products Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imdevimab in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c4aa9fca-28f9-4079-82fc-ae34af466035 GET /v1/drugs/c4aa9fca-28f9-4079-82fc-ae34af466035?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40063211000001105",
"desc": "Imdevimab 120mg/ml solution for infusion 11.1ml vials (Roche Products Ltd)",
"form": "Solution for infusion",
"vpid": "39658211000001100",
"source": "dmd",
"vtm_id": "1162696005",
"strength": "120 mg",
"substance": "Imdevimab",
"ingredient": "Imdevimab",
"supplier_code": "2085201000001100"
}See everything about imdevimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.